Mounting evidence suggested that serum FGF21 levels were considerably greater in patients with NAFLD in comparison with the controls, and its levels were positively correlated with triglyceride and fasting insulin concentrations, and negatively associated with high-density lipoprotein cholesterol (HDL) and body mass index (BMI) (12). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.